Trader's Alert on Mid-Morning Skyrocketing Moves - Oramed Pharmaceuticals, Inc (NASDAQ:ORMP), Digital Ally, Inc (NASDAQ:DGLY)

Following U.S. Stocks are among the “Most Active” Stocks in the course of recent trading session, Tuesday: Oramed Pharmaceuticals, Inc (NASDAQ:ORMP), Digital Ally, Inc (NASDAQ:DGLY)

Oramed Pharmaceuticals, Inc (NASDAQ:ORMP), with shares climbed 62.72% is now trading at $7.55. The Stock is active as 1.28M shares changed hands versus its average volume of 51,733.00 shares. The company holds consensus target price of $30.00.

Digital Ally, Inc (NASDAQ:DGLY), with shares raised 21.31% is now trading at $15.01. The Stock is active as 2.70M shares changed hands versus its average volume of 322,124.00 shares. The company holds consensus target price of $4.00.

Latest NEWS regarding these Stocks are depicted underneath:

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Oramed Pharmaceuticals Inc. (ORMP), has the market capitalization of $ 50.30M. The beta value of the stock is 0.01. On the other hand the stock’s volatility for the week is 10.50%, and for the month is 5.18%. The stock’s price to book ratio is 1.98, however price to cash ratio is 2.06. Analyst’s mean recommendation regarding this stock is 2.00. (Where 1=Buy, 5=Sale).

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides.

Digital Ally Inc. (NASDAQ:DGLY)

On Monday, Digital Ally Inc. (DGLY), which develops, manufactures and markets advanced video surveillance products for law enforcement, homeland security and commercial applications, declared its operating results for the quarter and full year ended December 31, 2014. An investor conference call is planned for 11:15 a.m. EDT tomorrow, March 24, 2015.

The Corporation also offered preliminary financial guidance for the year ending December 31, 2015. Based upon information presently accessible, the Corporation believes that its 2015 proceed should raise to about $25 million and that operating revenue should approximate $2.5 million, absent any unanticipated non-recurring expenses.

Highlights for Year Ended December 31, 2014:

Total proceed reduced 2% to about $17.4 million in 2014, contrast with about $17.8 million in the year ended December 31, 2013. Proceed in the fourth quarter of 2014 raised 55% to about $5.4 million, as compared to proceed of about $3.5 million in the final three months of the previous year.
Gross profit margin improved slightly to 56.9% of total proceed in 2014, contrast with 56.7% in 2013. For the fourth quarter of 2014, gross margin improved to 59.3% of proceed, representing a noteworthy improvement over the preceding-year quarter, when the gross margin was over 900 basis points lower at 49.9% of proceed.
Selling, general and administrative expenses raised 4% from year-earlier levels.
The Corporation stated an operating loss of ($2,889,194) for the full year 2014, contrast with an operating loss of ($2,250,442) in the previous year. However, the operating loss in the fourth quarter of 2014 was reduced by 79% to ($336,833), when contrast with an operating loss of ($1,573,958) in the preceding-year period.
A net loss of ($9,163,261), or ($3.54) per share, was recorded in the year ended December 31, 2014, contrast with a net loss of ($2,497,940), or ($1.17) per share, in 2013. About $5.8 million, or 87% of the year-over-year rise in net loss in 2014 (vs. 2013), was attributable to non-cash charges related to warrant derivative liabilities and changes in the fair value of secured convertible notes payable, together with note payable issuance expenses.
On a non-GAAP basis, the Corporation recorded an adjusted net loss of ($1,440,738), or ($0.56) per share, in 2014, contrast with a non-GAAP adjusted net loss of ($877,052), or ($0.41) per share, in the twelve months ended December 31, 2013. For the fourth quarter of 2014, the Corporation stated non-GAAP net revenue of $146,846, or $0.05 per diluted share, as compared to a non-GAAP net loss of ($1,116,204), or ($0.50) per share in the year-earlier period.
Shipments of the new DVM-800 digital in-car video system, which has become the Corporation’s “flagship” product after being introduced in the fourth quarter of 2013, accounted for 40% of the Corporation’s total sales in the year 2014.
Shipments of the FirstVU HD body cameras generated 11% of the Corporation’s total sales in the full year 2014, as compared to 3% in the previous year. FirstVU HD proceed raised to about 17% of total fourth quarter 2015 proceed.
As of December 31, 2014, over 800 law enforcement agencies were testing and evaluating more than 1,200 of the Corporation’s body-worn cameras. The Corporation has practiced a substantial raise in police department interest in its body camera products since widely publicized social unrest erupted in Ferguson, Missouri in August 2014.
The Corporation received its initial patent on the VuLink connectivity system, which allows Digital Ally’s in-car video systems and its FirstVU HD body cameras to work seamlessly together in gathering and recording evidence collection activities for law enforcement agencies.
The Corporation expanded its video evidence storage and administration solutions to comprise its VuVault.net cloud-based storage solution in the fourth quarter of 2014. This new product gives Digital Ally a competitive advantage by providing cloud storage for the FirstVU HD body camera and in-car video systems that can be synchronized to operate simultaneously using its patented VuLink product.

Digital Ally, Inc. develops, manufactures and markets advanced technology products for law enforcement, homeland security and commercial applications. The Corporation’s primary focus is digital video imaging and storage.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.